#Philadelphia #US #digital health #Pharmacovigilance #TransCelerate

Understanding the Role of Digital Health Technologies in Patient Safety

In a groundbreaking peer-reviewed publication in Therapeutic Innovation & Regulatory Science, TransCelerate BioPharma has delved into the pivotal role digital health technologies (DHTs) play in enhancing patient safety. This nonprofit organization is dedicated to accelerating clinical research and aims to improve global health outcomes. The article titled "Pharmacovigilance Data from Digital Health Systems Regulations, Implications, and Opportunities – A TransCelerate Perspective" sheds light on the intersection of regulatory practices and the rise of digital health tools in the biopharma industry.

Key Findings of the Research

As digital health tools proliferate, they are producing vast amounts of real-world data that pharmacovigilance teams are tasked with monitoring. However, the authors note significant challenges as safety information collection, definition, interpretation, and reporting require clarity amid increasing DHT adoption. The research team reviewed global regulations across six continents, complemented by literature and an industry survey involving 17 leading biopharma firms.

Regulatory Gaps and Challenges

The study finds a notable trend; although there’s increasing interest in DHTs, regulatory clarity for pharmacovigilance practices remains inconsistent. Most participating companies indicated that DHT-generated safety reports currently amount to less than 1% of overall annual safety reports, yet 76% of them expect this figure to rise as the adoption of digital health technologies continues to gain momentum.

Complicating matters, 59% of surveyed firms reported challenges in determining whether DHT-generated data constitute reportable adverse events. Surprisingly, while 82% of companies validate their digital health tools' technical aspects, less than half take it a step further into clinical validation. This disparity highlights the complexity of implementing DHTs into existing pharmacovigilance structures.

The Voice of Industry Experts

Jeneen Donadeo, Executive Director of Portfolio Management at TransCelerate, expressed that the industry is experiencing a surge in digital health technology integration. However, pharmacovigilance practices must navigate a rapidly changing regulatory environment without standardized definitions or clear regulatory expectations. The research identifies these challenges and suggests ways to bridge the gap, facilitating a more proactive approach to patient safety.

Introducing the Digital Health Pharmacovigilance Guide

Among the significant contributions of this research is a newly developed Digital Health Pharmacovigilance Considerations Guide. This resource aims to assist users in identifying the critical factors that will significantly impact pharmaceutical operations as they incorporate DHTs. To further support the industry, TransCelerate has also produced a comprehensive glossary of digital health terms, accessible in both English and Japanese.

Commitment to Ongoing Research

This publication is an extension of TransCelerate's long-standing efforts to interpret pharmacovigilance guidelines and regulations. The organization is deeply committed to fostering a shared understanding and delivering practical solutions in areas where the landscape is still evolving.

The full manuscript is available open access in Therapeutic Innovation & Regulatory Science, allowing broader industry insights and implications for advancing patient safety practices globally.

About TransCelerate BioPharma

TransCelerate BioPharma is driven by a vision to simplify and expedite clinical trials, ensuring that new therapies reach patients more effectively. With headquarters near Philadelphia, this nonprofit group has 18 member organizations and a diverse portfolio aimed at fostering connectivity and innovative trial methodologies. For further information, visit TransCelerate's website.